Short answer: A positive THC blood or serum test does not establish whether someone used prescribed medical cannabis or nonmedical cannabis. In a published pilot study that measured 18 cannabinoids and metabolites in serum, researchers found potentially informative patterns after certain specific medicines, including dronabinol and nabiximols (Sativex), but THC-rich medical cannabis and street cannabis could not be reliably distinguished. A chemical pattern can be consistent with a product or route of administration without proving its origin in an individual case.
Myth: A THC-positive blood test identifies the source of cannabis
Evidence: Delta-9-tetrahydrocannabinol (THC) is not a label identifying where the substance was obtained. Medicinal and nonmedical cannabis can contain the same principal cannabinoids, and biological testing measures chemical compounds in a specimen—not a prescription, supplier, purchase, or legal status.
In a 2021 pilot study, Scheunemann and colleagues investigated whether serum cannabinoid profiles might distinguish users of particular cannabis-based medicines from people using street cannabis. They analyzed 18 cannabinoids and metabolites with liquid chromatography–tandem mass spectrometry (LC-MS/MS), examined 56 serum samples from 23 study participants, and compared patterns with 55 previously analyzed forensic serum samples from street cannabis users. The central finding was narrower than an ability to “identify medical marijuana”: some formulation-related patterns were informative, but profiles from THC-rich medical cannabis and street cannabis substantially overlapped. Scheunemann et al., Metabolites (2021), DOI: 10.3390/metabo11050316.
What is a serum cannabinoid fingerprint?
A serum cannabinoid profile is a set of measured concentrations—or ratios—of cannabinoids and their metabolites in serum, the liquid fraction obtained after blood has clotted. Unlike a report limited to THC, an expanded panel may measure THC; 11-hydroxy-THC (THC-OH); 11-nor-9-carboxy-THC (THC-COOH); cannabidiol (CBD); cannabichromene (CBC); cannabigerol (CBG); and other minor cannabinoids or acidic precursors.
A profile describes the composition of the tested specimen at collection. An inference about the product, route, or dose additionally depends on pharmacokinetics, the time since exposure, prior use, the analytical method, the product’s changing composition, and alternative explanations. Findings from serum should not be transferred uncritically to venous whole blood, dried blood spots, urine, or oral fluid.
Myth: A high 11-hydroxy-THC-to-THC ratio proves dronabinol use
Evidence: The pilot study observed THC-OH/THC ratios of approximately 1 or more in the dronabinol and Sativex groups, while ratios were generally lower after inhaled plant cannabis. Such ratios may be compatible with a medicine and its route of administration, but they are not a validated universal cutoff that proves a named product, a lawful prescription, or a particular dose.
Interpretation is especially sensitive to route and timing: oral ingestion and inhalation create different concentration–time profiles, and both the numerator and denominator of a ratio change after use. The study was exploratory and did not establish the sensitivity, specificity, or error rate of a casework decision rule for all users. No single ratio should be presented to a jury as product-source identification without independent validation. Primary study.
Myth: CBD or minor cannabinoids prove a product was medical—or illicit
Evidence: The study reported CBD and CBC patterns that sometimes helped distinguish the THC/CBD oromucosal medicine Sativex from certain THC-dominant cannabis samples. Dronabinol samples generally contained relatively few minor cannabinoids. Plant cannabis could show higher levels of some minor constituents, including THCAA or CBGA. But these observations did not furnish a binary test for “legal medicine” versus “street cannabis.”
Two limits are crucial. First, the authors detected trace minor cannabinoids even in some samples from users of cannabis-based medicines. Their presence therefore cannot, by itself, establish additional illicit plant exposure. Second, medical cannabis flower and street cannabis can have overlapping botanical chemistry. The researchers could not separate the THC-rich medical-flower users from the street-cannabis group by their serum patterns. One sample after use of a CBD-rich medical strain appeared distinct, a hypothesis-generating result that was not proof of reliable strain attribution across patients. Source and study limitations.
What the actual evidence supports: a comparison
| Laboratory finding | Potentially supportable interpretation | Claim the study does not establish |
|---|---|---|
| THC detected in serum | THC was present in that serum specimen. | That the source was recreational rather than medicinal, or that the person was impaired at the time of an event. |
| THC-OH/THC ratio near or above 1 | May resemble patterns observed after some oral/oromucosal formulations in this pilot sample. | Confirmed dronabinol, Sativex, dose, or prescription compliance. |
| CBD and CBC alongside THC | May add information about formulation composition when combined with other analytes and context. | A unique marker of Sativex or a particular cannabis strain. |
| Numerous measurable minor cannabinoids | May fit exposure to a plant-derived mixture. | That the plant material was obtained unlawfully or could not be prescribed. |
| Few or undetected minor cannabinoids | May fit certain purified or THC-dominant products within assay limits. | That plant material was definitively not used. |
Myth: A multivariate model converts a suggestive pattern into definitive source identification
Evidence: The researchers used principal component analysis (PCA) and statistical comparisons to visualize differences among groups. PCA can help find structure in a multidimensional dataset; it does not automatically provide a prospectively validated individual-case classifier. The study also tested nine forensic serum samples from people reporting cannabis-based medicine use. Only one sample had a pattern consistent with the declared dronabinol use; the others resembled cannabis-user patterns, leading the investigators to consider possible additional exposure. Those findings remain interpretive, not conclusive proof that an individual misreported medication use.
The study’s limitations matter in litigation: it involved 23 participants and repeated samples from some individuals; medication use, timing, and additional cannabis exposure were largely self-reported; routes, doses, and sampling intervals varied; and knowledge of minor-cannabinoid detection windows was limited. The results were not a large, blinded forensic validation study designed to establish the accuracy of a source-identification rule. Scheunemann et al., results and limitations.
Source, exposure, impairment, and causation are four different questions
Measurement: Which compounds were detected, in what specimen, at what concentrations, and with which analytical uncertainty? Exposure inference: Is the observed pattern consistent with a described product or route? Functional impairment: Is there reliable evidence of diminished performance at the relevant time? Causation: Did an exposure contribute to the specific conduct or outcome alleged?
Evidence answering one question does not automatically answer the others. This serum-profiling study investigated possible exposure-source patterns; it did not establish an impairment threshold, test driving performance, determine causation, or validate distinctions between legal and illegal possession in any U.S. jurisdiction. For the separate evidentiary issue of screening versus impairment, see Cannabis Roadside Screening: Sensitivity Is Not Impairment. For a discussion of why a detected cannabinoid cannot precisely date use, see Residual THC in Frequent Cannabis Users.
Questions worth asking before offering a forensic source opinion
Was the specimen serum or whole blood? Were the full panel and measured concentrations disclosed, including limits of detection and quantification? Did the laboratory have validated methods for each minor cannabinoid? Is a proposed THC-OH/THC or CBD/THC cutoff derived from a sufficiently similar population and dosing route? Were sample timing, prior exposure, product formulation, analytical uncertainty, and competing sources considered? Has the laboratory demonstrated a false-classification rate for the specific claimed conclusion—or only exploratory separation of study groups?
Those questions are distinct from whether the chemical measurements themselves are accurate. For the broader process of reviewing laboratory materials, see How to Review a Toxicology Laboratory Packet.
Frequently asked questions
Can a positive THC test tell whether cannabis was prescribed?
No. A positive THC result identifies a chemical measurement, not the legal or medical provenance of the product. Even expanded serum panels did not distinguish THC-rich prescribed flower from street cannabis in this pilot study.
Can serum testing suggest dronabinol or Sativex use?
Potentially. A combination of THC metabolite ratios and minor-cannabinoid measurements showed patterns associated with those formulations in a small pilot population. “Consistent with” is more defensible than “proves,” and case-specific interpretation requires independent validation.
Does an 11-hydroxy-THC/THC ratio above 1 prove oral THC?
No. It can be compatible with some oral or oromucosal exposures, but the study did not validate a universal binary threshold for route, product, or dose identification.
Does the presence of THCAA or other minor cannabinoids prove illicit marijuana use?
No. Minor cannabinoids can occur in plant cannabis products used medically and, at low levels, in some manufactured cannabis-based medicines. Presence alone does not determine product provenance.
Can the study establish driving impairment from serum THC?
No. The investigators studied cannabinoid concentration patterns and possible sources, not a driving-performance threshold or causal link to an event.
Primary scientific reference
Scheunemann A, Elsner K, Germerott T, Groppa S, Hess C, Miederer I, Poplawski A, Röhrich J. Identification of Potential Distinguishing Markers for the Use of Cannabis-Based Medicines or Street Cannabis in Serum Samples. Metabolites. 2021;11(5):316. https://doi.org/10.3390/metabo11050316. PMID: 34068332.